ciprofloxacin has been researched along with Scleroderma, Systemic in 3 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Similar effects were observed in SSc-interstitial lung disease (ILD) lung fibroblasts." | 1.38 | Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1. ( Bujor, AM; Christmann, RB; Haines, P; Junie, M; Lafyatis, R; Padilla, C; Sampaio-Barros, PD; Trojanowska, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bujor, AM | 1 |
| Haines, P | 1 |
| Padilla, C | 1 |
| Christmann, RB | 1 |
| Junie, M | 1 |
| Sampaio-Barros, PD | 1 |
| Lafyatis, R | 1 |
| Trojanowska, M | 1 |
| Ozgocmen, S | 1 |
| Kaya, A | 1 |
| Coskun, BK | 1 |
| Over, KE | 1 |
| Bucknall, RC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind Randomized Clinical Trial to Evaluate the Reduction of Pain in the Wounds Treatment Previously Applying Lidocaine Topical Solution vs Placebo, in the Outpatients Area.[NCT03676556] | Phase 3 | 46 participants (Anticipated) | Interventional | 2021-06-16 | Recruiting | ||
| Randomised, Double-blind Clinical Trial to Evaluate the Reduction of Pain in the Wounds Treatment Previously Applying Lidocaine Topical Solution vs Placebo[NCT02584335] | Phase 4 | 7 participants (Actual) | Interventional | 2015-07-31 | Terminated (stopped due to Difficulties with the recruitment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for ciprofloxacin and Scleroderma, Systemic
| Article | Year |
|---|---|
Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1.
Topics: Cartilage Oligomeric Matrix Protein; Case-Control Studies; Cells, Cultured; Ciprofloxacin; Collagen | 2012 |
Topical lidocaine helps reduce pain of digital ulcers in systemic sclerosis (scleroderma).
Topics: Administration, Oral; Administration, Topical; Anesthetics, Local; Anti-Infective Agents; Ciprofloxa | 2006 |
Topical lidocaine helps reduce pain of digital ulcers in systemic sclerosis (scleroderma).
Topics: Administration, Oral; Administration, Topical; Anesthetics, Local; Anti-Infective Agents; Ciprofloxa | 2006 |
Topical lidocaine helps reduce pain of digital ulcers in systemic sclerosis (scleroderma).
Topics: Administration, Oral; Administration, Topical; Anesthetics, Local; Anti-Infective Agents; Ciprofloxa | 2006 |
Topical lidocaine helps reduce pain of digital ulcers in systemic sclerosis (scleroderma).
Topics: Administration, Oral; Administration, Topical; Anesthetics, Local; Anti-Infective Agents; Ciprofloxa | 2006 |
Regression of skin changes in a patient with systemic sclerosis following treatment for bacterial overgrowth with ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Diarrhea; Female; Humans; Middle Aged; Scleroderma, Systemic; | 1998 |